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Abstract. The standard paradigm for the analysis of genome-wide as-
sociation studies involves carrying out association tests at both typed
and imputed SNPs. These methods will not be optimal for detecting
the signal of association at SNPs that are not currently known or in
regions where allelic heterogeneity occurs. We propose a novel associa-
tion test, complementary to the SNP-based approaches, that attempts
to extract further signals of association by explicitly modeling and es-
timating both unknown SNPs and allelic heterogeneity at a locus. At
each site we estimate the genealogy of the case-control sample by tak-
ing advantage of the HapMap haplotypes across the genome. Allelic
heterogeneity is modeled by allowing more than one mutation on the
branches of the genealogy. Our use of Bayesian methods allows us to as-
sess directly the evidence for a causative SNP not well correlated with
known SNPs and for allelic heterogeneity at each locus. Using simu-
lated data and real data from the WTCCC project, we show that our
method (i) produces a significant boost in signal and accurately identi-
fies the form of the allelic heterogeneity in regions where it is known to
exist, (ii) can suggest new signals that are not found by testing typed
or imputed SNPs and (iii) can provide more accurate estimates of effect
sizes in regions of association.
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1. INTRODUCTION
Over the last two years genome-wide association
studies have been successful in uncovering novel dis-
ease causing variants [2, 3, 7, 21, 28–30]. All of these
studies have proceeded by testing for associations at
SNPs assayed by a commercial genotyping chip and
many have also used genotype imputation methods
[13] to test untyped SNPs, especially when combin-
ing studies that used different genotyping chips to
carry out larger meta-analysis studies.
It is possible that signals of association will be
missed by these methods and there are several ways
in which this could happen. First, the true causal
variant, which may be a SNP but could also be an
Indel or Copy Number Variant (CNV), may not be
on the chip or on the typed reference panel and may
not be in sufficient Linkage Disequilibrium (LD) with
a single typed or imputed SNP for a signal to be de-
tected. If this is the case the variant may be well
identified by considering a local haplotype in the re-
gion, thus the association may be detected if such
effects are tested for association. Second, it may be
the case that the causal model of association in the
region involves more than one SNP. One way to de-
scribe this model would be to say that there is allelic
heterogeneity in the association signal. If the SNPs
are in LD then the various haplotypes that consist
of the causal SNPs may have distinct relative risks.
If this is the case then the model might also be de-
scribed as a haplotype effect model.
In this paper we investigate a method that is com-
plementary to SNP-based association tests that al-
lows for these more complex disease models. To go
beyond testing typed or imputed genetic variants
we need to construct a model for genetic variation
that has not been directly observed. We achieve this
by modeling the genealogy of the sample of chro-
mosomes at each point along the genome and then
estimating genotypes, in the case-control samples,
at SNPs derived by placing mutations on the in-
dividual branches of the tree. The genotypes that
are derived from the local genealogies can then be
associated with the phenotype under study, which
we test using Bayesian methods that naturally ac-
count for the inherent uncertainty in the location of
the disease mutation on the genealogy. Some pre-
vious approaches that have used genealogical trees,
have either been applicable only to haplotype data
with no missing data [4, 27] or computationally pro-
hibitive and thus restricted to small samples [10, 33].
The method that we present here is applicable to
genotype data with missing data and is computa-
tionally feasible to analyze thousands of individuals
across the whole genome (it requires approximately
the same amount of computational resources as im-
putation [13]). A novel feature of our method is that
we can take advantage of the HapMap haplotypes to
build the genealogical trees at each putative risk lo-
cus.
We provide an informal description of the method
first and full technical details of the method are
given in the Methods section. Our approach pro-
ceeds in several stages:
(i) We use a panel of known haplotype variation,
such as HapMap [6], and an estimate of the fine-scale
recombination rate (such as that available from the
HapMap website), to construct an approximation
to the genealogy of the sample of haplotypes in the
panel, at each point on a grid of positions across the
genome.
(ii) For each such tree, we then, in turn, consider
putative mutations on each of its branches. Once
the branch for a mutation is chosen, this will fix
the alleles carried by chromosomes at each of the
tips of the tree. Assuming such a SNP exists in the
population, we use a population genetics model to
predict the likely genotypes at this SNP in each case
and control individual (we call these the study in-
dividuals). This is perhaps simplest to conceptual-
ize under the simplifying assumption that we had
haploid data on the study individuals. The popula-
tion genetics model allows us to place each haploid
study chromosome (probabilistically) on the tips of
the genealogical tree: each tip contains a single panel
haplotype, and the study haplotype will tend to be
placed on the tips corresponding to panel haplotypes
that are locally similar to it. For diploid study data
there is an additional level that, in effect, averages
over likely local phasings of the data. The result, for
each study individual, is a probability distribution
over the possible genotypes at the putative SNP.
(iii) The next step takes the predicted genotypes
with their uncertainties and looks for evidence of
association with disease status. (Note the need to
handle appropriately the uncertainty over the pre-
dicted genotypes.) We do this here in a Bayesian
framework. For a particular genomic location and
putative SNP, the evidence for association is nat-
urally measured by a Bayes factor [13] (BF) that
compares a model of association with a null model
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of no association. The uncertainty over the possible
branch carrying the mutation is handled by averag-
ing over the Bayes factors for each branch, to give a
single BF summarizing the evidence for the presence
of a causative mutation at that position.
(iv) To allow for possible allelic heterogeneity, we
can extend the analyses above by putting two (or
more) putative mutations on the genealogical tree
and predicting genotypes for the pair of SNPs in
study individuals, before fitting disease models with
multiple causative mutations. We would then av-
erage over pairs of positions for the mutation in
calculating a BF for the strength of evidence for
a 2-mutation disease model at that position, com-
pared to the null hypothesis, and by comparing the
2-mutation BF with the single mutation BF, one can
assess the relative evidence for allelic heterogeneity,
for example.
(v) At genomic positions where there is a signal
of association, we can combine the estimated tree
with the most likely mutation pattern to character-
ize graphically the signal of association, and identify
which local haplotypes show evidence of differential
disease risk between cases and controls.
We have applied our method to data from the
Wellcome Trust Case Control Consortium (WTCCC)
[28] to assess its performance and illustrate its novel
features. Specifically, we have applied it to several
risk loci that are known to exhibit allelic hetero-
geneity (e.g., the NOD2 region for Crohn’s disease)
and show that our method provides a boost in signal
over testing both typed and imputed SNPs. In addi-
tion we show that the method can accurately iden-
tify the branches on the genealogy that correspond
to the true causal variants. Further we have applied
the method across the genome for all seven diseases
studied by WTCCC and have compared its perfor-
mance to testing both typed and imputed SNPs.
Our method is able to identify (subsequently vali-
dated) associations not picked up by tested typed or
imputed SNPs and results in a much richer charac-
terization of the associated signal in several regions.
We show that no one method is optimal in detecting
association but that the new method presented here
clearly have a role to play in detecting and char-
acterizing associations in genome-wide scans. Our
use of Bayesian methods allows the Bayes factors
at both typed and imputed SNPs to be naturally
combined with the Bayes factors produced by our
method.
We also carried out some simulation studies that
highlight additional features of our approach. First,
we examine how well our method does at uncovering
allelic heterogeneity where it exists. We show that
this can be quite a hard problem but our method
does have good power to uncover the action of more
than one causal variant. Second, we consider the
problem of estimating the effect size of a causal vari-
ant in an associated region in the specific case where
the causal variant is not well tagged by a typed SNP.
We show that our method is able to provide a more
accurate estimate of the effect size in this case.
The next section describes the details of our meth-
ods and this is followed by a section on the analy-
sis of the WTCCC data and simulation studies. We
conclude with a discussion of the results and the
likely applications of our method.
2. METHODS
We use Hi = {H1, . . . ,HN} to denote a set of N
known haplotypes, where Hi = (Hi1, . . . ,HiL) is a
single haplotype, Hij ∈ {0,1} and L is the num-
ber of SNP loci. For all the analysis in this paper
we have set H to be the 120 CEU haplotypes esti-
mated as part of the HapMap project [6]. We let G=
{G1, . . . ,GK} denote the genotype data for theK in-
dividuals in a new study, where Gi = (Gi1, . . . ,GiL)
and Gij ∈ {0,1,2,missing}. It is likely that many
of the genotypes will be missing since genome-wide
SNP chips do not contain every SNP in the HapMap
panel. We use Φi ∈ {0 = Control,1 = Case} to de-
note the binary phenotype of the ith individual. Let
X = {X1, . . . ,XM} be a grid of physical positions
for carrying out association tests; for our analysis,
we use a grid spacing of 5 kb on every chromosome.
Step 1. A genealogical tree, T , is constructed at
every position in X using the set of known haplo-
types. The trees are built using the coalescent model
with recombination and approximate the posterior
modal tree given the haplotypes. To do this it is
useful to be able consider P (T |H) under the coales-
cent. Using the Bayes Formula we can rewrite this
as: P (H|T )P (T )/P (H). Although it is simple to cal-
culate these values under the coalescent with simple
mutation models it is not known how to simulate
directly from this distribution, or how to produce
trees that maximize this expression [26].
To make this task simpler it is helpful to factorize
this expression into the individual events that make
up the tree (coalescence, recombination or muta-
tion). It is useful to note that trees augmented with
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mutation track the haplotypes backward in time,
and these haplotypes change after each event. Note
that P (T ) =
∏
iP (Ei) where i indexes the events
backwards in time and Ei is the ith event. Also
P (T |H) =
∏
iP (Ei|Hi), where Hi denotes the hap-
lotypes as changed by the first i events. Then, note
that P (Ei|Hi) = P (Hi|Ei)P (Ei)/P (Hi).
It is not known how to calculate P (Hi) directly.
However, as the coalescent is Markov backward in
time P (Hi|Ei) (the probability of the haplotypes
Hi given that the next event backwards in time
is Ei) is equal to P (Hi+1) (the probability of the
haplotypes as changed by the event Ei). So to cal-
culate P (Ei|Hi) it is only necessary to calculate
(P (Hi+1)/P (Hi))P (Ei). For all types of event (coa-
lescence, recombination or mutation) the quotients
P (Hi+1)/P (Hi) simplify to give terms of the form
P (Hn+1|H1, . . . ,Hn). These terms still cannot be
calculated efficiently under the coalescent, however
they are amenable to approximation using Hidden
Markov Models [5, 11].
Once these values can be approximated it is possi-
ble to generate a tree that approximates the modal
posterior tree as follows:
1. Initialize: Decide on mutation model, recombina-
tion rates, and initialize the haplotypes, H0, as
the set of known haplotypes input to the method.
2. Recursion (steps 2 through 6): Enumerate all pos-
sible events that may be the next event back-
wards in time.
3. For each of these events approximate P (Ei|Hi),
the posterior probability of each event, as de-
scribed above.
4. Choose the event with the highest posterior prob-
ability.
5. Generate haplotypes Hi+1 by applying the cho-
sen event to haplotypes Hi.
6. Stop: When each locus has reached its common
ancestor the process terminates.
We used the recombination rates estimated from
the HapMap [6], and an infinite sites mutation model
for this analysis. This step needs only be performed
once for each set of reference haplotypes. For ex-
ample, we have calculated and stored a set of trees
for the CEU HapMap haplotypes across the genome
at a grid of positions with a 5 kb spacing between
positions. Trees produced by this method (called
TREESIM) may be useful for other population ge-
netics inferences.
Step 2. Given the genealogical tree at a given po-
sition, Xm, estimated in step 1 our method works
by averaging over locations of the disease causing
mutations on branches, b, of the tree. Each muta-
tion defines a hypothetical disease SNP that can be
added into the panel of haplotypes. For each indi-
vidual we use a model to calculate the expected al-
lele count for this disease mutation at the position
Xm. We use H
mb to denote the set of haplotypes,
H , augmented with the disease SNP at the posi-
tion Xm created by a mutation on branch b and
Gmbi to denote the genotype vector for study indi-
vidual i augmented with the (unknown) genotype
for the branch b disease SNP at position Xm. We
use a model similar to that used in IMPUTE [13]
that relates each individual’s genotype vector to the
set of known haplotypes, P (Gmbi |H
mb), as a Hidden
Markov Model in which the hidden states are a se-
quence of pairs of the N known haplotypes in the
set H . That is,
P (Gmbi |H
mb) =
∑
Z
(1)
i
,Z
(2)
i
P (Gmbi |Z
(1)
i ,Z
(2)
i ,H
mb)
· P (Z
(1)
i ,Z
(2)
i |H
mb),
where Z
(1)
i = {Z
(1)
i1 , . . . ,Z
(1)
id , . . . ,Z
(1)
i(L+1)} and Z
(2)
i =
{Z
(2)
i1 , . . . ,Z
(2)
id , . . . ,Z
(2)
i(L+1)} are the two sequences of
hidden states at the L + 1 sites, Z
(j)
il ∈ {Z
(2)
i1 , . . . ,
Z
(2)
id , . . . ,Z
(2)
i(L+1)}, and d is the position of the disease
SNP in the augmented sets Hmb and Gmbi . These
hidden states can be thought of as the pair of haplo-
types in the set H that are being copied to form the
genotype vector Gmbi . The term P (Z
(1)
i ,Z
(2)
i |H
mb)
defines our prior probability on how sequences of
hidden states change along the sequence and
P (Gmbi |Z
(1)
i ,Z
(2)
i ,H
mb) models how the observed geno-
types will be close to but not exactly the same as
the haplotypes being copied.
The expected genotype at the disease SNP can be
defined as
embi =E(G
mb
im )
=
N∑
k1=1
N∑
k2=1
(I(Hmbk1m = 1) + I(H
mb
k2m
= 1))
· pim(k1, k2),
where I is the indicator function and
pim(k1, k2)
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= P ({Z
(1)
im ,Z
(2)
im }= {k1, k2}|G
mb
i ,H
mb)
∝ P (Gmbi |{Z
(1)
im ,Z
(2)
im }= {k1, k2},H
mb)
=
∑
Z
(1)
i
,Z
(2)
i
:
{Z
(1)
im
,Z
(2)
im
}={k1,k2}
P (Gmbi |Z
(1)
i ,Z
(2)
i ,H
mb)
· P (Z
(1)
i ,Z
(2)
i |H
mb).
This step involves a calculation that is practi-
cally identical to that used in the method IMPUTE,
which has been used in several genome-wide analy-
ses to date, and illustrates that the method is prac-
tical for this type of analysis.
Step 3. The final step involves evaluating whether
there is evidence of association at each position by
calculating a BF between a model of association M1
and a model of no association M0. The simplest way
of modeling association at the disease SNP created
by placing a mutation on branch b at position Xm
is to create a 2× 2 table of expected allele counts
0 1
Controls n00 = nU − n01 n01 =
∑
i:Φi=0
embi
Cases n10 = nA − n11 n11 =
∑
i:Φi=1
embi
where nU and nA are the numbers of unaffected
(control) and affected (case) haplotypes respectively.
From this table we can calculate a Bayes factor as
BFmb =
P (Data|M1)
P (Data|M0)
, where
P (Data|M1)
=
∫
P (Φ|emb, θ1;M1)P (θ1|M1)dθ1
=
∫
pn11(1− p)n01
Γ(a+ c)
Γ(a)Γ(c)
pa−1(1− p)c−1 dp
·
∫
qn10(1− q)n00
Γ(a+ c)
Γ(a)Γ(c)
qa−1(1− q)c−1 dq
=
Γ(n11 + a)Γ(n01 + c)
Γ(n0+ a+ c)
·
Γ(n10 + a)Γ(n00 + c)
Γ(n1 + a+ c)
·
[
Γ(a+ c)
Γ(a)Γ(c)
]2
,
where p and q are penetrance parameters of the al-
leles 1 and 0 respectively, and
P (Data|M0)
=
∫
P (Φ|emb, θ0;M0)P (θ0|M0)dθ0
=
∫
rnA(1− r)nU
Γ(a+ c)
Γ(a)Γ(c)
ra−1(1− r)c−1 dr
=
Γ(nA + a)Γ(nU + c)
Γ(nA + nU + a+ c)
Γ(a+ c)
Γ(a)Γ(c)
,
where r is a penetrance parameter unconditional on
allele. These calculations utilize a Binomial likeli-
hood for the expected allele counts and a Beta(a, c)
prior on the parameters of the model. For the anal-
ysis of the WTCCC data in this paper we used a
Beta(20,30) prior the parameters p, q and r in the
models. This prior is centered on the proportion of
cases and controls in the sample and leads to a dis-
tribution on the relative risk (p/q) with mean 1.0
and standard deviation of 0.49. Supplementary Fig-
ure 3 illustrates the prior on the relative risk.
The additive model of association we have used is
the simplest option and was chosen initially for com-
putational convenience. One criticism of this model
is that it implicitly makes an assumption of Hardy–
Weinberg Equilibrium (HWE) at the SNP in both
cases and controls and is more susceptible to the
effects of population structure [22]. To ameliorate
these concerns we have also developed a facility to
output estimated (or imputed) genotypes, in the
case-control samples, at SNPs derived by placing
mutations on the individual branches of the tree.
These SNP genotypes can be fed directly into our
software SNPTEST thus allowing a range of more
sophisticated models to be applied to the data, such
as standard additive, dominant, recessive and gen-
eral tests of association and tests that condition on
covariates and testing of other more refined pheno-
types. This facility is used in one of our simulation
studies where we investigate the performance of our
method in estimating effect sizes in associated re-
gions.
A Bayes factor for the position Xm can be ob-
tained by averaging the Bayes factors for each branch,
b, weighted by the prior, P (b), on each branch that
was estimated in step 1:
BFm =
∑
b∈B
BFmbP (b).
We take P (b), the prior probability of a mutation
occurring on a branch b, to be proportional to the
expected length of b under the coalescent, that is,
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∑n
i=m
2.0
i(i−1) , where m and n are the number of dis-
tinct branches when b was first formed and just be-
fore m coalesced respectively. Our prior favors mu-
tations that occur on long branches.
An analogous set of calculations can be carried
out by assuming that there exist two (or more) dis-
tinct disease mutations on branches of the tree at
each position. The prior probability of mutations on
more than one branch is simply the product of the
probabilities of mutation occurring on each individ-
ual branch.
2.1 Posterior Probability of the Number
of Mutations
Let BF 1 and BF 2 be the Bayes factor under the
1-mutation model (M1) and 2-mutation model (M2)
respectively, then the Bayes factor, BF , comparing
the 2-mutation model to the 1-mutation model is
given by
BF =
P (D|M2)
P (D|M1)
=
P (D|M2)/P (D|M0)
P (D|M1)/P (D|M0)
=
BF 2
BF 1
,
where D is data and M0 is the null model. If we
assume a prior odds for two mutations vs. one mu-
tation of 1 : 1 then the posterior odds is simply BF ,
the ratio of BF 2 and BF 1.
3. RESULTS
3.1 Application to NOD2 Locus
To illustrate the utility of our method on an estab-
lished disease locus exhibiting allelic heterogeneity
we applied our approach to the NOD2 locus [9, 19]
for Crohn’s disease on chromosome 16. We applied
our approach to this region using a set of trees built
using the CEU HapMap haplotypes at 5 kb intervals
throughout the region. We used, after filtering, 1748
case and 2938 control individuals genotyped as part
of the WTCCC study.
The results produced by our method are shown in
Figure 1, which compares the signals of association
at SNPs on the Affymetrix chip, imputed SNPs and
two versions of our method that allow one and two
mutations on the tree at each position respectively.
All the methods show a substantial signal at the lo-
cus but the signal for our new methods are higher
and broader. The signals are also much smoother
across the region than the signals from the typed
and imputed SNPs. The log10 Bayes factors allowing
for one and two mutations peak at 11.44 and 13.33
respectively (larger values of the Bayes factor indi-
cate stronger evidence for association). These com-
pare favorably with the log10 Bayes factors at the
best Affymetrix SNP (12.00) and the best imputed
SNP (11.42); so the new method provides a stronger
signal than comparable current approaches.
Next we can assess the relative evidence for the
2-mutation model compared with the 1-mutation
model simply by dividing the relative Bayes factors,
or equivalently through the difference of the log10
Bayes factors. Here the latter is 1.89, indicating that
the data is about 101.89 = 78 times more likely under
the 2-mutation model than the 1-mutation model. If
the 1- and 2-mutation models were thought equally
likely a priori this would imply a posterior probabil-
ity of 0.987 for two mutations versus one mutation
indicating substantial evidence of allelic heterogene-
ity.
There are three known coding SNPs in this region
[9, 19]. Two of these SNPs (rs2066845 and rs2066844)
are in the HapMap panel. Figure 1 shows that the
three distinct haplotypes induced by these two SNPs
correspond well to those identified by the best fitting
2-mutation model. For example, one of the two best
mutations (red) precisely identifies the CEU haplo-
types that carry the rare rs2066845 mutation while
the other mutation (green) is only one branch away
from precisely identifying the haplotypes that carry
the more common rs2066844 mutation. In other words,
our analyses of the WTCCC data using the new
method go very close to recovering the known pat-
tern of disease susceptibility, based on much more
extensive genotyping. Relative risk estimates of red
and green mutations on the tree, relative to a lack
of either of these mutations, are 2.15 and 1.56 re-
spectively.
3.2 Application to the WTCCC Data
We have applied this method to all seven genome-
wide association studies carried out as part of the
WTCCC study [28]. Doing this allows us to com-
pare the performance of the new method to those
methods that are currently routinely used to ana-
lyze genome-wide association studies, that is, anal-
ysis of genotyped SNPs on the chip and of imputed
SNPs.
Table 1 lists the regions that exhibited a log10
Bayes factor greater than 4 for either the 1-mutation
or the 2-mutation model. Just as with p-values, there
is no correct threshold for Bayes factors for “declar-
ing” association. Several arguments suggest that the
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threshold on which we focus here is quite a stringent
one. Empirically, many SNPs with lower single-SNP
Bayes factors in the WTCCC data are now known
to correspond to real effects, and most or all SNPs
meeting this threshold have been replicated. On a
theoretical level, this is the required threshold in or-
der for the posterior odds of association at a site to
be greater than 1 when using a prior odds of associa-
tion of 1/10,000. This prior is motivated by the argu-
ment that there are on the order of 1,000,000 “inde-
pendent” regions of the genome and an expectation
of 100 of these being involved in the disease. Most of
Fig. 1. The top left panel of the plot shows the log10 Bayes factor for the 1-mutation model (red) and 2-mutation model (green)
within the NOD2 region of the Crohn’s Disease analysis. The recombination map (red line) and the cumulative recombination
map (purple line) are shown below this. The bottom left panel shows the 120 CEU HapMap haplotypes across the region. Each
row of this panel is a haplotype and each column is a SNP. The haplotypes are colored to indicate the three haplotypes that occur
at the 2 coding SNPs rs2066844 and rs2066845 (red = CC, purple = TG, cyan = CG). The dashed vertical blue and brown
lines indicate the position of the largest log10 Bayes factor for the 2-mutation model (the focal position) and the two coding
SNPs respectively. The bottom right panel shows the estimated genealogical tree at the focal position. The x-axis of the plot was
chosen to provide a clear view of all the branches in the tree. The branches associated with the best 1-mutation and 2-mutation
models that make the largest contributions to the Bayes factors are shown with blue and red/green dots respectively. The top
right panel shows the tables of expected allele counts for the 1-mutation and 2-mutation models together with a summary of
the Bayes factors that occur at the focal position. The columns of the tables are color matched to the mutations on the tree in
the bottom right panel.
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Table 1
Regions that exhibited a log10 Bayes factor greater than 4 for either the 1-mutation or the 2-mutation model in the analysis
of the seven WTCCC diseases. Log10 Bayes factors for 1-mutation and 2-mutation models are given together with the
posterior probability of the 2-mutation model relative to the 1-mutation model. Log10 Bayes factors and p-values are also
given for the best Affymetrix SNP and best imputed SNP in the regions
1-mutation 2-mutation Prob. Affy. IMPUTE Affy. IMPUTE
Disease Chr. Region (Mb) Log10 BF Log10 BF 2 mut. Log10 BF Log10 BF p-value p-value
CAD 9 21.98–22.11 11.04 11.01 0.48 11.66 11.58 1.79e−14 1.48e−14
CD 1 67.25–67.47 12.96 17.99 1.00 10.07 15.82 6.45e−13 7.93e−18
CD 2 233.93–233.99 10.38 10.29 0.45 11.11 11.55 7.10e−14 2.79e−14
CD 5 40.33–40.65 10.45 14.68 1.00 10.41 10.93 2.13e−13 1.32e−13
CD 5 131.65–131.83 5.82 6.13 0.67 4.54 7.18 5.40e−07 3.04e−10
CD 5 150.16–150.3 4.94 4.89 0.47 5.43 5.51 4.26e−08 3.15e−08
CD 6 31.36–31.39 4.61 4.69 0.55 1.96 6.52 0.000254 5.63e−08
CD 6 31.99–32.52 4 4.75 0.85 1.4 3.33 0.00106 7.13e−07
CD 10 101.27–101.29 5.32 5.4 0.55 5.91 6.05 1.41e−08 1.03e−08
CD 16 49.16–49.44 11.44 13.33 0.99 12 11.42 5.78e−15 7.20e−17
CD 18 12.77–12.87 5.56 5.52 0.48 5.42 5.53 4.56e−08 1.72e−09
RA 1 113.59–114.26 20.73 20.81 0.55 22.36 11.87 4.90e−26 3.92e−18
RA 6 29.66–33.77 102.92 124.67 1.00 74.84 91.19 3.44e−76 1.98e−106
T1D 1 113.59–114.23 20.76 20.7 0.47 23.07 13.21 1.17e−26 1.98e−18
T1D 4 123.59–123.88 4.59 4.58 0.49 4.42 5.63 5.00e−07 2.24e−07
T1D 6 25.98–33.93 290.18 >300 1.00 306.95 202.71 1.02e−287 2.28e−204
T1D 10 6.13–6.15 4.35 4.85 0.76 3.31 4.58 7.97e−06 3.19e−07
T1D 12 54.66–54.78 7.65 7.72 0.54 8.89 8.02 1.14e−11 2.30e−11
T1D 12 109.83–111.48 10.98 10.98 0.50 12.53 12.74 2.17e−15 2.06e−16
T1D 15 58.57–58.58 3.2 4.06 0.88 1.08 1.98 0.00242 4.46e−05
T1D 16 10.97–11.12 5.2 5.24 0.52 5.76 6.27 2.22e−08 8.50e−09
T2D 6 20.79–20.81 4.04 4.15 0.56 4.15 4.35 1.02e−06 1.01e−07
T2D 9 22.12 5.61 5.71 0.56 1.53 2.90 0.000706 2.22e−05
T2D 10 114.72–114.81 9.73 9.89 0.59 10.14 11.09 5.68e−13 6.08e−14
T2D 16 52.36–52.38 5.01 5.11 0.56 5.89 5.74 1.44e−08 2.07e−08
the regions in this table were identified by the SNP
and imputation analysis of the main WTCCC study
but there are some notable differences.
There are three regions for the Crohn’s disease
analysis for which the posterior probability for two
mutations is very close to 1.0. The first of these is
the NOD2 region described above. The second is
the IL23R locus on chromosome 1, which is another
established disease locus for Crohn’s disease with ex-
tensive known allelic heterogeneity [3]. A plot show-
ing the results of our method in this region is given
in Figure 2. The log10 Bayes factors, at the IL23R
locus, are 12.96 and 17.99 for the 1-mutation and
2-mutation models respectively, which compare fa-
vorably with the best Affymetrix SNP (10.07) and
the best imputed SNP (15.82). The difference be-
tween the 2-mutation and 1-mutation Bayes factors
implies a posterior probability of 1.00 for two muta-
tions versus one mutation, indicating overwhelming
evidence of allelic heterogeneity.
The original paper [3] identified two SNPs in func-
tional regions of the IL23R gene. The first SNP
(rs11209026) is the nonsynonymous SNP (c.1142G>
A, p.Arg381Gln) identified as the strongest signal in
the original study. The second SNP (rs10889677) is
in the 3′ UTR of the IL23R gene and the only other
associated nonintronic SNP found in the original
study. When we look at these two SNPs in the CEU
HapMap panel we identify three distinct haplotypes
colored green, purple and blue in Figure 2. These
haplotypes are almost precisely those that are de-
lineated by the two mutations that make the largest
contribution to the 2-mutation Bayes factor. One
of the mutations on the tree (colored red) identifies
all the CEU HapMap haplotypes that carry the A
allele at rs11209026 and the second mutation (col-
ored green) identifies all but one of the haplotypes
that carry the A allele at rs10889677. Relative risk
estimates of red and green mutations on the tree,
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relative to a lack of either of these mutations, are
0.39 and 1.29 respectively.
Another signal for Crohn’s disease is located within
an approximately 250 kb region on chromosome 5,
flanked by recombination hotspots. Numerous SNPs
within this region have been identified and repli-
cated [1, 12] (p-values down to 10−12 in combined
analysis). The LD structure delineates this region
into five LD blocks and the strongest associations
(single SNP and haplotype) were found in a cen-
tral 122 kb block. However, multivariate haplotype
analysis conditional on the effect of the central block
showed that the two flanking LD blocks remain sig-
nificantly associated [12], which suggests that mul-
tiple variants in the region may account for the ob-
served effects on Crohn’s disease.
Single SNP analysis in the WTCCC dataset re-
veals strong associations at both Affymetrix and
imputed SNPs (maximum log10 Bayes factors 10.41
and 10.92, respectively). Figure 3 illustrates the re-
sults of our analysis. The 2-mutation model provides
a large boost in signal (maximum log10 Bayes factor
14.68) and compared to the 1-mutation model (max-
imum log10 Bayes factor 10.45) strongly support al-
lelic heterogeneity at this locus (posterior probabil-
ity of 2-mutation model vs. 1-mutation model is 1.0).
Further, the two mutations that make the largest
contribution to the 2-mutation Bayes factor, appear
to delineate the HapMap haplotypes in three groups
with distinct LD pattern approximately 100 kb ei-
ther side of the position of the maximum Bayes
factor under the 2-mutation model, at 40,430,000
(NCBI Build 35 coordinates), which we call the fo-
cal position. Relative risk estimates of red and green
mutations on the tree, relative to a lack of either of
these mutations, are 1.80 and 1.29 respectively.
In addition to the signals identified by the tested
typed and imputed SNPs in the main WTCCC anal-
ysis, we find two other signals: one for Type 2 Dia-
betes (T2D) on chromosome 9 and one for Type 1
Diabetes (T1D) on chromosome 15.
The Type 2 Diabetes signal on chromosome 9 re-
sides within a 9 kb region flanked by recombination
hot spots. This locus was identified and confirmed
by three independent T2D genome-wide association
studies [23, 24, 31], which reported rs10811661 with
the strongest signal of association. The p-values at
this SNP were 7.6 × 10−4 in the WTCCC study
[31], 5.4 × 10−4 in the DGI study [24] and 2.2 ×
10−3 in the FUSION study [23]. A meta-analysis
of the pooled samples from all three studies [31],
which comprised of 14,586 cases and 17,968 controls,
yielded a p-value of 7.8× 10−15. A haplotype anal-
ysis of this region also identified a significant signal
in this region and the existence of a high-risk hap-
lotype carrying the T alleles at SNPs rs10811661
and rs10757283 (see Supplementary Material of ref.
[11]).
Single SNP analyses of the WTCCC data revealed
a moderate signal at rs10811611 of log10 Bayes fac-
tor 1.53, which is the strongest within the 9 kb re-
gion flanking the recombination hotspots (stronger
signals are located approximately 100 kb away but
are likely to be related to another signal associated
with rs564398). Figure 4 summarizes our results in
this region. The maximum log10 Bayes factors peak
at 5.61 and 5.71 for the 1-mutation and 2-mutation
models. These signals represent a significant boost
in power to detect this locus. The 2-mutation model
provides a better fit than the 1-mutation model sug-
gesting evidence of allelic heterogeneity in the re-
gion. Relative risk estimates of red and green muta-
tions on the tree, relative to a lack of either of these
mutations, are 1.30 and 0.90 respectively.
One of the mutations on the tree (colored red)
exactly identifies all but one of the HapMap hap-
lotypes that contain the high risk TT haplotype at
SNPs rs10811661 and rs10757283. The other mu-
tation on the tree (colored green) identifies a pro-
tective CT haplotype at the SNPs rs10811661 and
rs10757283 that was not mentioned in the original
analysis.
A possible novel signal is located at chromosome
15q22.2 for T1D (Figure 5), where no previous asso-
ciations have been identified. Single SNP tests only
detected a very weak signal in this region (log10
Bayes factor peak at 1.08 and 1.98 at Affymetrix and
imputed SNPs respectively). The maximum log10
Bayes factor from the 2-mutation model (4.06) is
stronger than the 1-mutation model (3.20), which
provides some suggestion that multiple causal vari-
ants are involved. The focal position of our signal is
located in the RORA gene, which encodes ROR, an
evolutionarily related transcription factor and be-
longs to the steroid hormone receptor super family.
RORA has been linked to immunomodulatory ac-
tivities [15], which might make RORA a candidate
gene for autoimmune diseases such as T1D.
We also looked at the WTCCC data in detail at
the relatively large number of established disease
genes for Crohn’s disease [1] (30 loci) and Type 2 Di-
abetes [32] (18 loci). Not all of these loci were found
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Fig. 2. The top left panel of the plot shows the log10 Bayes factor for the 1-mutation model (red) and 2-mutation model (green)
within the IL23R region of the Crohn’s disease analysis. The recombination map (red line) and the cumulative recombination
map (purple line) are shown below this. The bottom left panel shows the 120 CEU HapMap haplotypes across the region. Each
row of this panel is a haplotype and each column is a SNP. The panel haplotypes are colored to indicate the three haplotypes
that occur at the 2 coding SNPs rs11209026 and rs10889677 (blue = AC, purple = GC, green = GA). The dashed vertical
blue and brown lines indicate the position of the largest log10 Bayes factor for the 2-mutation model (the focal position)
and the two coding SNPs, respectively. The bottom right panel shows the estimated genealogical tree at the focal position.
The x-axis of the plot was chosen to provide a clear view of all the branches in the tree. The branches associated with the best
1-mutation and 2-mutation models that make the largest contributions to the Bayes factors are shown with blue and red/green
dots respectively. The top right panel shows the tables of expected allele counts for the 1-mutation and 2-mutation models
together with a summary of the Bayes factors that occur at the focal position. The columns of the tables are color matched to
the mutations on the tree in the bottom right panel.
to be highly significant in the WTCCC study. We
compared tests at (i) SNPs on the Affymetrix 500k
chip, (ii) imputed SNPs, and the (iii) 1-mutation
and (iv) 2-mutation versions of our new method.
The results for the Crohn’s Disease and Type 2 Di-
abetes regions are shown in Figures 6 and 7 respec-
tively. The results show that no one method uni-
formly produces the largest signal across all of the
regions. Out of all the 48 regions together, the four
methods produced the largest signal in 12, 30, 1 and
5 regions respectively. These results show that in
13% of the regions of known association the meth-
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Fig. 3. The top left panel of the plot shows the log10 Bayes factor for the 1-mutation model (red) and 2-mutation model
(green) within a chromosome 5 region of the Crohn’s disease analysis. The recombination map (red line) and the cumulative
recombination map (purple line) are shown below this. The bottom left panel shows the 120 CEU HapMap haplotypes across
the region. Each row of this panel is a haplotype and each column is a SNP. The panel haplotypes are colored red and beige
to represent the two-allele types at each SNP. The dashed vertical blue line indicates the position of the largest log10 Bayes
factor for the 2-mutation model (the focal position). The bottom right panel shows the estimated genealogical tree at the focal
position. The x-axis of the plot was chosen to provide a clear view of all the branches in the tree. The branches associated with
the best 1-mutation and 2-mutation models that make the largest contributions to the Bayes factors are shown with blue and
red/green dots respectively. The top right panel shows the tables of expected allele counts for the 1-mutation and 2-mutation
models together with a summary of the Bayes factors that occur at the focal position. The columns of the tables are color
matched to the mutations on the tree in the bottom right panel.
ods described in this paper lead to an increase in
signal over and above that of testing directly typed
and imputed SNPs (although in some cases the in-
crease in signal is small). The results also reinforce
our previous findings [13] that imputation can pro-
vide a nontrivial boost in power over testing only
those SNPs that have been genotyped directly.
3.3 Power to Detect Allelic Heterogeneity
The real examples shown above illustrate that when
allelic heterogeneity exists in a region of association
our method can accurately characterize the under-
lying risk variants and lead to a boost in signal.
We have also used simulation to assess the power of
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Fig. 4. The top left panel of the plot shows the log10 Bayes factor for the 1-mutation model (red) and 2-mutation model (green)
within a chromosome 9 region of the Type 2 Diabetes disease analysis. The recombination map (red line) and the cumulative
recombination map (purple line) are shown below this. The bottom left panel shows the 120 CEU HapMap haplotypes across
the region. Each row of this panel is a haplotype and each column is a SNP. The panel haplotypes are colored red and beige
to represent the two allele types at each SNP. The dashed vertical blue line indicates the position of the largest log10 Bayes
factor for the 2-mutation model (the focal position). The bottom right panel shows the estimated genealogical tree at the focal
position. The x-axis of the plot was chosen to provide a clear view of all the branches in the tree. The branches associated with
the best 1-mutation and 2-mutation models that make the largest contributions to the Bayes factors are shown with blue and
red/green dots respectively. The top right panel shows the tables of expected allele counts for the 1-mutation and 2-mutation
models together with a summary of the Bayes factors that occur at the focal position. The columns of the tables are color
matched to the mutations on the tree in the bottom right panel.
our method to distinguish the signal of allelic het-
erogeneity when it exists. To do this we extended
our program HAPGEN [25] to simulate SNP geno-
type datasets, in 2000 cases and 2000 controls, un-
der a model of allelic heterogeneity with two linked
causal SNPs. HAPGEN conditions on a reference
panel of haplotypes and their local recombination
rates to create genotype datasets that naturally in-
herit the patterns of LD found in the reference panel.
Datasets were generated by using the 120 CEU
parental HapMap haplotypes in five ENCODE re-
gions (ENr123, ENr213, ENr232, ENr321 and
ENm013) as reference panels; each dataset is ap-
proximately 500 kb in length with a SNP density
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Fig. 5. The top left panel of the plot shows the log10 Bayes factor for the 1-mutation model (red) and 2-mutation model
(green) within a chromosome 15 region of the Type 1 Diabetes disease analysis. The recombination map (red line) and the
cumulative recombination map (purple line) are shown below this. The bottom left panel shows the 120 CEU HapMap haplotypes
across the region. Each row of this panel is a haplotype and each column is a SNP. The panel haplotypes are colored red and
beige to represent the two allele types at each SNP. The dashed vertical blue line indicates the position of the largest log10
Bayes factor for the 2-mutation model (the focal position). The bottom right panel shows the estimated genealogical tree at
the focal position. The x-axis of the plot was chosen to provide a clear view of all the branches in the tree. The branches
associated with the best 1-mutation and 2-mutation models that make the largest contributions to the Bayes factors are shown
with blue and red/green dots respectively. The top right panel shows the tables of expected allele counts for the 1-mutation and
2-mutation models together with a summary of the Bayes factors that occur at the focal position. The columns of the tables
are color matched to the mutations on the tree in the bottom right panel.
of approximately two SNPs per kb. For the set of
haplotypes required by step 1 of our method we pro-
duced pseudo-HapMap panels by thinning the EN-
CODE data to match the SNP density and MAF
distribution of the phase II HapMap data, with the
added restriction that this panel contain the SNPs
on the Affymetrix 500k chip. Each dataset was sim-
ulated at all SNPs in the ENCODE regions but only
genotype data at the SNPs on the Affymetrix 500k
chip were presented to the method in step 2.
To simulate instances of allelic heterogeneity we
selected pairs of SNPs within 15 kb of each other,
and satisfying the condition of either Model A or
Model B (described below), as the causal SNPs for
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Fig. 6. Comparison of the performance of four different methods in the WTCCC data at the 30 established associated loci
for Crohn’s disease. The plot shows the maximum log10 Bayes factor for imputed SNPs (black) and the 1-mutation (red) and
2-mutation (green) versions of our new method (on the y-axis), plotted against the maximum log10 Bayes factor at Affymetrix
SNPs (on the x-axis), in each region.
a dataset. We exhaustively searched for all suitable
pairs in the five ENCODE marker sets and for each
pair generated a single dataset, comprised of 2000
case and 2000 control individuals. The minor allele
was set to be the deleterious allele at both SNPs and
phenotypes were simulated according to the marginal
relative risks given to each disease allele.
For each simulated dataset we compared the max-
imum 1-mutation and 2-mutation Bayes factors. Ta-
bles 2 and 3 show the results of this comparison for
two disease models that we simulated: Model A, one
rare causal SNP with risk allele frequency less than
2% and one common causal SNP with risk allele
frequency between 5% and 20%, and Model B, two
causal SNPs with a risk allele frequency between 5%
and 20%.
The tables show the proportion of times that the
2-mutation signal is larger than that for the 1-mutation
model. We also show results for just those simulated
datasets where there is an appreciable signal of as-
sociation (log10 Bayes factor > 3). In general, these
results show that our method has good power to de-
tect allelic heterogeneity when the effect sizes at the
susceptibility loci are similar to those found in our
analysis of the WTCCC data. For example, when
the relative risks are 2.5 and 1.3 at the rare and com-
mon SNPs for Model A our method has 70% power
to detect a larger signal for the 2-mutation model.
If we consider only those simulations in which the
signal is appreciably large (log10 Bayes factor > 3)
then this power rises to 83%. Similarly for Model
B, when the relative risks are 1.5 and 1.3 at the
susceptibility SNPs our method has 67% power to
detect a larger signal for the 2-mutation model and
this power rises to 69% when conditioning only on
large signals. As effect sizes become smaller there is
less power to detect an effect and it also becomes
more difficult to distinguish between one and two
mutations. When there is no effect at either locus,
that is, under the “null hypothesis” of no associa-
tion, we obtain a false positive rate of close to zero
when conditioning upon appreciable signals.
BAYESIAN METHOD 15
Fig. 7. Comparison of the performance of four different methods in the WTCCC data at the 18 established associated loci
for Type 2 Diabetes. The plot shows the maximum log10 Bayes factor for imputed SNPs (black) and the 1-mutation (red) and
2-mutation (green) versions of our new method (on the y-axis), plotted against the maximum log10 Bayes factor at Affymetrix
SNPs (on the x-axis), in each region.
Table 2
Results of simulations of allelic heterogeneity at two linked causal SNPs using Model A: one rare with risk allele frequency
less than 2% and one common with risk allele frequency between 5% and 20%. Relative risks at the two simulated loci are
shown in the first two rows. The maximum 1-mutation and 2-mutation log10 Bayes factors are denoted by S1 and S2
respectively. The third row shows the proportion of simulated datasets where S2 was greater than S1. The fourth row shows
the proportion of simulated datasets that had S2 > 3. The fifth row shows the proportion of simulated datasets where S2 was
greater than S1 conditional upon S2 > 3. The final row shows the expected difference between S2 and S1 conditional upon
S2 > 3
RRA (rare causal SNP) 1.0 1.0 1.5 2.0 2.5
RRB (common causal SNP) 1.0 1.3 1.3 1.3 1.3
Pr(S2 > S1) 0.07 0.33 0.45 0.61 0.70
Pr(S2 > 3) 0.00 0.13 0.18 0.37 0.57
Pr(S2 > S1|S2 > 3) — 0.52 0.69 0.81 0.83
Mean(S2 − S1|S2 > 3) — 0.07 0.20 0.59 0.73
3.4 Estimating Effect Sizes in Associated
Regions
In associated regions it is standard practice to re-
port the effect size of the risk allele at the associated
SNP and it is usual that this takes the form of the
estimated Relative Risk (RR) or Odds Ratio (OR)
of the allele together with a 95% confidence inter-
val. Such estimates are useful for approximating the
magnitude and precision of the association in the
study population, quantifying the amount of heri-
tability explained by the locus and predicting indi-
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vidual disease risk. As we have seen above, testing
for association at typed and imputed SNPs can be
successful in detecting associated regions but this is
not always the case and our method is sometimes
able to detect a larger signal, effectively by more
accurately characterizing the true causal variant. It
follows that in these cases our method may also be
able to accurately estimate the effect size of the true
causal variant. To investigate this idea we carried
out a simulation study using the ENCODE region
ENm013 from the CEU HapMap haplotypes and
the thinned pseudo-HapMap panel that we created
for our simulation study in the previous section. We
searched for all SNPs in the ENCODE region that
had an R2 with any SNP in the pseudo-HapMap
panel of at most 0.2 and used these SNPs as the
causal SNPs in our simulations. These SNPs will
be not be in high LD with any of the SNPs on the
Affymetrix 500k chip and are unlikely to be imputed
well. For each causal SNP we then simulated a case-
control study in the region using HAPGEN. Each
causal SNP was used four times with simulated rel-
ative risks of 1.25, 1.5, 2.0 and 2.5. Only genotype
data at the SNPs on the Affymetrix 500k chip were
simulated. We then analyzed the data in two differ-
ent ways to obtain an approximate posterior distri-
bution on the effect size.
Firstly, we considered the estimated effect size at
the most associated Affymetrix SNP in the region.
We used a logistic regression model and fitted an
additive model on the log odds scale implemented
by SNPTEST to calculate the mode of the pos-
terior distribution of additive effect parameter, βˆ.
The OR estimate is subsequently calculated as eβˆ .
The prior on the effect size was that used in the
WTCCC study [28].
We then obtained an analogous estimate and stan-
dard errors from our method GENECLUSTER in
the following way. We first identified the locus Xm,
where the maximal 1-mutation Bayes factor occurred.
For each branch, b, on the genealogical tree con-
structed at this position we placed a mutation on
the branch and calculated the posterior probabil-
ity that the ith individual carried 0, 1 or 2 copies
of the mutation, P (Gmbi |H
mb). We then took these
genotype distributions at all individuals and used
SNPTEST to carry out a test of association at the
SNP implied by the mutation on the branch using
the same additive logistic regression model as above.
This resulted in a posterior estimate of βb and its
standard error σ2b . The posterior distribution can be
calculated by summing over the branches of the tree,
that is,
P (β|Data) =
∑
b
P (β, b|Data)
=
∑
b
P (β|b,Data)P (b|Data)
∝
∑
b
P (β|b,Data)P (Data|b)P (b)
∝
∑
b
P (β|b,Data)BF bP (b),
where BF b is the Bayes factor associated with branch
b and P (b) is the prior probability on branch b car-
rying a causal mutation. If we assume that the pos-
terior distribution of the additive genetic effect pa-
rameter conditional on a given branch, P (β|b,Data),
can be approximated using a Normal distribution
N(βˆb, σˆ
2
b ) then the overall estimate will be a mixture
of Normal distributions with each branch weighted
by its associated Bayes factor and its prior. From
Table 3
Results of simulations of allelic heterogeneity at two linked causal SNPs using Model B: both causal SNPs with a risk allele
frequency between 5% and 20%. Relative risks at the 2 simulated loci are shown in the first two rows. The maximum
1-mutation and 2-mutation log10 Bayes factors are denoted by S1 and S2 respectively. The third row shows the proportion of
simulated datasets where S2 was greater than S1. The fourth row shows the proportion of simulated datasets that had S2 > 3.
The fifth row shows the proportion of simulated datasets where S2 was greater than S1 conditional upon S2 > 3. The final
row shows the expected difference between S2 and S1 conditional upon S2 > 3
RRA 1.0 1.0 1.1 1.3 1.5
RRB 1.0 1.3 1.3 1.3 1.3
Pr(S2 > S1) 0.05 0.32 0.38 0.55 0.67
Pr(S2 > 3) 0.00 0.21 0.33 0.56 0.81
Pr(S2 > S1|S2 > 3) — 0.44 0.47 0.56 0.69
Mean(S2 − S1|S2 > 3) — 0.04 0.04 0.17 0.41
BAYESIAN METHOD 17
this model we can obtain a new estimate of the ef-
fect size as
βˆ∗ =
1
K
∑
b
βˆbBF bP (b),
where K =
∑
bBF bP (b). The OR estimate is subse-
quently calculated as eβˆ
∗
.
We compared these two estimates of the effect
size to the true estimate of the effect size, which
we calculated by fitting the same logistic regres-
sion model to the simulated data at the true causal
SNP. Figure 8 shows the distribution of the differ-
ence between the estimated effect size minus the
true effect size for both methods. In constructing
this plot we only considered simulations that showed
a maximal log10 Bayes factor for the 1-mutation
GENECLUSTER model above 4. The plot shows
that GENECLUSTER outperforms the use of the
best Affymetrix SNP when estimating the effect size.
The mean square error for the OR estimate is 1.037
for the best Affymetrix SNP estimate and 0.524 for
the GENECLUSTER method.
4. DISCUSSION
The standard paradigm for the analysis of genome-
wide association studies involves testing both typed
and imputed SNPs and then attempting to repli-
cate interesting signals in new datasets. In this pa-
per, we have proposed a complementary method
that attempts to extract further signals of associ-
ation first by explicitly considering as-yet-unknown
SNPs in the region, and second by modeling and
estimating allelic heterogeneity at a locus. Allelic
heterogeneity has been predicted to play a signifi-
cant role in the genetic etiology of complex diseases
[20] and clear examples in real human data already
exist (Figures 1–3). Our method works by locally ap-
proximating the genealogy of the haplotypes in the
sampled individuals and then averaging over the dif-
ferent branches of the genealogy as potential sites of
casual mutations using a Bayesian approach.
A key feature of our approach is the use of a ge-
nealogical tree to represent the relationship between
the haplotypes of the sample and to effectively con-
strain the space of possible causal variants consid-
ered. The genealogical tree, built in step 1 using fine-
scale haplotype data at each position, greatly aids
interpretation of the signal. As illustrated in Figures
1–5, we are able to accurately estimate the best sin-
gle branch, and pair of branches on the tree, that
make the largest contribution to the signal of asso-
ciation. Since the tree is built using only the set of
HapMap haplotypes we are able to graphically link
the tree to the haplotypes themselves, which acts
to highlight the haplotypic backgrounds that harbor
the estimated causal mutations. Our analyses in this
paper are based on a set of genealogical trees built
at 5 kb intervals and testing for association at those
locations. The 5 kb interval size was chosen based
on the SNP densities of our data in the HapMap ref-
erence panel, which is approximately one SNP per
kb, and in the study sample, which is approximately
one SNP per 6 kb. Using an excessively small inter-
val size compared to the SNP densities in the refer-
ence panel and study sample will likely yield highly
a set of correlated trees (in step 1), clusterings of
the study sample genotypes (in step 2) and hence
signals for association (in step 3). However, some
brief analyses indicate that 5 kb could be a conser-
vative estimate and a higher density, for example,
one tree per 1 kb, can increase power and lead to
a finer resolution for the location of the putative
disease locus (results not shown). There is little dis-
advantage in testing at more locations, apart from
the linear increase in the computation burden, and
since modern association study data are typed at an
increasingly dense set of SNPs, we recommend im-
plementing GENECLUSTER using as dense a set of
trees as computation resources allow.
For the analysis in this paper our method was ap-
plied using one estimated genealogy at each posi-
tion on a grid of positions across the genome. By
using a single tree at each position it is straightfor-
ward to visualize which branches, or combination of
branches, drive the signal of association. The disad-
vantage is that the uncertainty in the genealogy is
ignored. Our method is currently being extended to
allow multiple trees at each position in order to cap-
ture the uncertainty in the genealogy but it is not
clear whether this will lead to a significant boost in
performance and we have left this for future work.
However, we feel encouraged by the performance of
our current method in its ability to accurately iden-
tify known allelic heterogeneity and to boost signals
of association in real data and simulated data (see
Supplementary Material).
The second step of our method involves locally
clustering the genotype data to the tips of the es-
timated genealogy. A key feature of our model is
that we are not constrained to choose a “window”
of SNPs, as required by many haplotype clustering
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Fig. 8. Comparison of methods for estimating the effect size. Both plots show the distribution of the difference between the
estimated and true odds ratio. The left hand plot shows the results when using the best chip SNP to estimate odds ratio.
The right-hand plot shows the results when using GENECLUSTER.
methods [16–18], and instead we are able to use
hundreds of flanking SNPs around the focal locus
to both build the genealogical trees and cluster the
genotype data to the tips of the tree. Our method
also naturally handles missing data and takes hap-
lotype uncertainty into account and thus avoids re-
lying on a point estimate of haplotypes [27] as this
has been shown to produce nonoptimal results [14].
We encourage the use of the most accurate recom-
bination map possible but experience using simi-
lar HMM models for imputation suggests that the
models are reasonably robust to varying the recom-
bination rates. The mutation rates in our models
are fixed and constant across SNPs. It could be ar-
gued that estimating them in a SNP-by-SNP fash-
ion might help down weight the influence of SNPs
with high genotyping error rates, but this would add
considerably to the computational expense of the
method and since genotyping error rates are low we
do not think this would make a noticeable improve-
ment to our method.
The third step in our method involves placing one
or more mutations on the estimated genealogy and
evaluating the evidence of association between those
mutations and the phenotype data of those geno-
types clustered to the tips of the tree. We set our
prior probability of a mutation occurring on a given
branch to be proportional to the expected branch
length, which is based on the assumption that mu-
tations are more likely to occur on longer branches
and every mutation has an equal prior probability of
being causal. This means that our prior probability
on rare mutations being causal will be small since
they tend to occur on shorter branches. We can also
adjust our prior to favor mutations that occur on the
shorter branches to boost our power to detect rare
variants. However, our ability to detect rare causal
variants will also be limited by the characterization
of rare variants in the HapMap reference panel (as
discussed below).
Thus far we have only considered placing at most
two mutations on a single genealogy but our ap-
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proach can be easily extended to placing further mu-
tations. However, there is a considerable increase in
computation burden with placing more mutations
due to the increase in the set of possible combina-
tions of branches carrying a mutation. For exam-
ple, the complexities of the 3-mutation and the 4-
mutation models increase by approximately 79 and
4600 times, respectively, compared to the 2-mutation
model. It is therefore feasible to implement the 3-
mutation model for analyses of small regions, for
example for fine-mapping, but not genome-wide. A
possible compromise would be to employ a Markov
chain Monte Carlo approach to integrate over the
space of branches carrying a mutation.
A key approximation that we make, which is wor-
thy of some discussion, is to construct the genealog-
ical tree using only the reference sample of HapMap
haplotypes and then probabilistically cluster the study
individuals under the tips of the tree at each locus.
In doing this we effectively construct a genealogical
tree for the whole sample. In contrast, the MAR-
GARITA method [14] attempts to construct the full
genealogy of the sample but only in the study indi-
viduals and using a rather heuristic method for im-
plicitly phasing the genotype data. In doing so this
method ignores the information available from the
HapMap haplotypes in a given region.
The advantages of using the HapMap data are
that the haplotypes are accurately phased and con-
sist of a higher SNP density than commercially avail-
able genotyping chips. Both of these properties aid
the reconstruction of the genealogical tree. In ad-
dition there are computational advantages in be-
ing able to produce a set of genealogies across the
genome just once and then storing the trees for all
future use. A limiting feature of the HapMap haplo-
types is the relatively small size of the sample, that
is, there are only 120 CEU haplotypes. In many re-
gions of the genome the HapMap haplotypes will
provide a good representation of the common set
of haplotypes likely to be found in the population
but there will clearly be regions where this is not
true. Also, the HapMap will not provide a compre-
hensive characterization of the rare haplotype struc-
ture present in the population. It is clear that there
are instances in which our method of building ge-
nealogies will not be perfect but the application to
seven genome-wide scans of the WTCCC has clearly
shown that the method is able to detect and accu-
rately characterize real associations where they oc-
cur. This is likely due to the fact that it is common
variants that show association at these loci and our
method is able to accurately characterize the rele-
vant common haplotype structure.
We have carried out a small amount of compar-
ison between GENECLUSTER and MARGARITA
on selected loci. At the chromosome 9 locus for Type
2 Diabetes discussed above and shown in Figure 4
we found that MARGARITA was not able to un-
cover a significant association (permutation p-value
0.2498), whereas significant signals at other loci ex-
amined in this paper were found. A more compre-
hensive comparison of these methods is complicated
by the fact that MARGARITA produces results in
terms of p-values whereas GENECLUSTER’s infer-
ence is Bayesian.
At loci where there is an especially large genetic
effect the true underlying genealogy of the study
sample may differ quite a lot to that of the geneal-
ogy of the sample of HapMap haplotypes. In this
scenario the case haplotypes will be strongly clus-
tered under the branch of the tree that contains
the disease susceptibility mutation whereas control
haplotypes will tend to be biased away from cluster-
ing under this branch. Thus in this case using the
HapMap haplotypes to build a genealogy may not
be optimal. As the effect size gets smaller, however,
this bias is reduced and we do not see this as a seri-
ous concern for analysis of genome-wide association
studies where effect sizes are typically small.
A more complete method would involve the con-
struction of the genealogical tree at each position us-
ing all the data. This is complicated by the fact that
the study individuals consist of unphased genotype
data, whereas the HapMap haplotypes are phased,
and consist of missing data at many SNPs that are
in HapMap but not on the genotyping chip. One can
envisage an iterative scheme in which phasing and
imputation of missing alleles in the study individ-
uals and building of genealogical trees are carried
out, but this would likely be computationally pro-
hibitive, unless other simplifying assumptions are
made. Strictly speaking it would also be necessary
to build the genealogical tree and fit a disease model
at the same time and this would add a further layer
of complexity.
We expect that the performance of our method
will show a similar pattern of variation to that of im-
putation when applied in other populations [8] since
the underlying models are quite similar. Applying
the method to admixed individuals or to studies in-
volving individuals from different populations is not
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something we have considered here and we would
encourage caution in directly applying the method
in such situations. This may be an interesting av-
enue for future research.
We see two possible ways in which our method
could be used. First, and foremost, we see it as a
complementary method to testing typed and im-
puted SNPs across the genome. The method is de-
signed to pick up signals that have a more complex
structure than ones single SNP models can accom-
modate. Our results on the WTCCC datasets above
show that the method is able to boost signal in re-
gions where this occurs. For example, in the 48 es-
tablished regions of association for Crohn’s disease
and Type 2 Diabetes our new methods produced the
largest signal in 13% of the regions. A distinction be-
tween our approach and the SNP-based approaches
is that we jointly assess the data at all SNPs com-
patible with the genealogy for evidence of associa-
tion. Therefore, at each location, GENECLUSTER
assesses the evidence for association at any SNP,
whereas SNP-based approaches perform a single test
at each SNP for association. This means that in re-
gions with a SNP (typed or imputed) that is ei-
ther causal, or in strong LD with a causal SNP,
GENECLUSTER is likely to produce a lower Bayes
factor than a direct test at that SNP, and we expect
that this is the case for most of the regions in our
comparison since they were identified using SNP-
based approaches. However, our results also show
that there is an appreciable number of regions in the
genome where GENECLUSTER outperforms SNP-
based approaches, namely regions with a causal vari-
ant that is not well tagged by the data, or with mul-
tiple causal variants. The Supplementary Material
details a further simulation study that we have car-
ried out to show that our method is well powered
to detect signals of association compared to simpler
tag-based approaches.
Our use of a Bayesian framework allows the re-
sults of a GENECLUSTER analysis to be naturally
combined together with the analysis of imputed and
typed SNPs. The Bayes factors from each approach
can be combined together into one set across the
genome, and interesting signals can be identified
by applying a Bayes factor threshold that is de-
termined by the prior probability of an association.
This prior probability represents the proportion of
the genome that we expect to be associated with
the disease, which remains fixed and independent of
the number of tests carried out. This means that
our method can be naturally and easily accommo-
dated into the analysis without recourse to Frequen-
tist multiple testing procedures. In our analysis, we
have assumed 1/10,000th of the genome is truly as-
sociated [28]. Determining a threshold for the Bayes
factor involves the use of decision theory and the
specification of a loss function. When focusing on
identifying a set of SNPs for follow-up replication,
we might penalize a false nondiscovery more than
a false discovery. When making a final decision on
a SNP after replication data has been collected, we
might penalize a false discovery more than a false
nondiscovery. To illustrate our method and compare
methods we have used a 0/1 loss function that gives
equal weight to false discoveries and false nondiscov-
ery and represents the middle ground between these
two scenarios. This results in a common threshold of
4 for the log10 Bayes factors at typed SNPs, imputed
SNPs and GENECLUSTER. We do not expect the
comparison between methods to be influenced by
this choice.
Our method could be used in a more focused fash-
ion, in fine-mapping experiments, to investigate the
form of the association in regions already identi-
fied by single SNP methods and to produce bet-
ter estimates of effect sizes. For example, if the ap-
plication of the 1-mutation version of the method
leads to a clear boost in signal over typed and im-
puted SNPs then this may indicate the presence of
an undiscovered causal SNP. Further application of
the 2-mutation version may subsequently indicate a
much stronger signal implying allelic heterogeneity
within the region, such as at the NOD2, IL23R and
5p13 associated regions for Crohn’s disease (Fig-
ures 1–3), and lead to the accurate identification
of the haplotype backgrounds with elevated disease
risk. This can aid selection of individuals for rese-
quencing in fine-mapping studies (data not shown)
and lead to better prediction of disease risk in un-
phenotyped individuals. A clear advantage of using
Bayesian methods in our approach is that it allows
us to directly estimate the probability of two muta-
tions versus one mutation.
As noted above, we use a model averaging ap-
proach in which we are interested in whether a lo-
cation is associated with the disease. Another op-
tion would be not to carry out this model averaging
and to test each branch of the tree with its own
Bayes factor. It would be interesting to compare
these two approaches in more detail and will be rel-
atively straightforward since GENECLUSTER can
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output probabilistic genotype calls associated with
placing a mutation on each branch of the tree. In
the new approach, we will obtain a sample of Bayes
factors rather than a single Bayes factor at each lo-
cation as before. Therefore, it is likely that we will
obtain larger Bayes factors in associated regions but
the smoothness of the signal we noted above will
likely disappear. Nevertheless, in the context of fine-
mapping signals, to characterize the underlying form
of an association and estimate effect sizes, it clearly
makes sense to consider each branch of the tree in
its own right as we have done.
4.1 The WTCCC Data
We used the same set of filtered WTCCC data
used by the main study [28]. All regions of potential
association had genotypes at flanking SNPs checked
by examining the intensity cluster plots. SNPs with
borderline quality cluster plots were removed and
the analysis was re-run to assess the impact on the
results.
Software Implementation
Our software, called GENECLUSTER, will be made
publicly available at the time of publication from
the website http://www.stats.ox.ac.uk/˜marchini/
software/gwas/gwas.html.
This incorporates the TREESIM method for sam-
pling marginal genealogical trees at a given site con-
ditional upon a set of haplotypes.
Our other software packages, HAPGEN, IMPUTE
and SNPTEST, are also available from this website.
Supplementary Material
Supplementary material to this paper is available
from http://www.stats.ox.ac.uk/˜marchini/papers/
GC SOM.pdf.
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